Tumor cell membrane proteins (TAA)

Tumor cell membrane proteins are a heterogeneous group of proteins expressed on the surface of neoplastic cells, encompassing receptors, transporters, enzymes, and adhesion molecules. These proteins are critical for the maintenance of the malignant phenotype, facilitating uncontrolled growth, resistance to apoptosis, and metabolic reprogramming (Source: Nature Reviews Cancer, 2021). Because many of these proteins are either uniquely expressed or significantly overexpressed on tumor cells compared to normal tissue, they serve as the foundation for targeted cancer therapies, including monoclonal antibodies and chimeric antigen receptor (CAR) T-cells (Source: NIH National Cancer Institute). Therapeutic strategies often involve the inhibition of oncogenic signaling or the use of these proteins as docking sites for the delivery of potent cytotoxic payloads (Source: PubMed, PMID: 33024317). Despite their success, challenges such as target heterogeneity within the tumor and potential toxicity to healthy tissues expressing the same markers remain significant hurdles in drug development (Source: StatPearls, 2023).

Other names

Tumor-associated antigensTumor-specific antigensCancer cell surface proteinsTumor surface markersCancer surfaceome

Mechanisms include competitive inhibition of ligand binding to receptors, induction of immune-mediated cell lysis such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and targeted delivery of cytotoxic chemicals or radionuclides via antibody-drug conjugates (Source: NIH National Cancer Institute).